| HBV cure: the main gaps to overcome | 10 April 2019 08:00 – 09:30 | ||
| Linking clinical endpoint of cure to novel biomarkers Anna LOK |
10 April 2019 08:00 – 08:30 | ||
| Current approaches to accelerate cure? What did we learn from recent studies? Thomas BERG |
10 April 2019 08:30 – 08:45 | ||
| Effect of HBV on infected hepatocytes: how does it impact cure ? Is cure possible? Jane McKeating |
10 April 2019 08:45 – 09:00 | ||
| Discussion: Is HBV cure possible and how is it defined? Where are the obstacles? Fabien ZOULIM Panelist: Thomas BERG, Markus Cornberg, Anna LOK, Jane McKeating, Peter Revill |
10 April 2019 09:00 – 09:30 | ||
| Coffee break | 10 April 2019 09:30 – 10:00 | ||
| Discussion – hot topics on HBV cure | 10 April 2019 10:00 – 11:00 | ||
| How to impact cccDNA kinetics by new treatments ? Do we need cccDNA quantification or epigenetic studies? Barbara Testoni |
10 April 2019 10:00 – 10:15 | ||
| How to overcome the defects in innate and adaptive immunity to cure HBV infection ? What are the technical requirements? Mala Maini |
10 April 2019 10:15 – 10:30 | ||
| Discussion: What are the best concepts to cure HBV? What are the technical requirements? How should we do the studies? Fabien ZOULIM Panelist: Thomas BERG, Markus Cornberg, Anna LOK, Mala Maini, Peter Revill, Barbara Testoni |
